Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541388 | 0.99 | PPARA (0.41) | PPARAPPARGCYSLTR2CYSLTR1FAAH | |
| SCHEMBL20738909 | 0.97 | PPARA (0.41) | PPARAPPARGCYSLTR2CYSLTR1FAAH | |
| SCHEMBL19578800 | 0.94 | PPARA (0.41) | PPARAPPARGCYSLTR2CYSLTR1FAAH | |
| SCHEMBL24608668 | 0.91 | PPARG (0.38) | PPARAPPARGCYSLTR2CYSLTR1FAAH | |
| SCHEMBL22541366 | 0.90 | PPARA (0.38) | PPARAPPARGFAAHSLC6A2SLC6A4 | |
| SCHEMBL20738344 | 0.85 | IDO1 (0.39) | PPARAPPARGFAAHSLC6A2SLC6A4 | |
| SCHEMBL21015050 | 0.85 | SLC6A2 (0.39) | PPARAPPARGFAAHSLC6A2SLC6A4 | |
| SCHEMBL19578799 | 0.84 | PPARG (0.38) | PPARAPPARGFAAHSLC6A2SLC6A4 | |
| SCHEMBL31287576 | 0.82 | PPARG (0.49) | PPARAPPARGSLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19697159 | 0.81 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | PPARA 215/4885PPARG 198/4885CYSLTR2 452/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | PPARA 215/4885PPARG 198/4885CYSLTR2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.